Results of PDR treatments: The AMC PDR experience

B. R. Pieters, E. D. Geijsen

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 %. The incidence of grade 2–3 rectal complications is limited (12–15 %). The incidence of grade 2–3 urinary toxicity is 15–26.9 %. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.
Original languageEnglish
Title of host publicationInterstitial Prostate Brachytherapy
PublisherSpringer Berlin Heidelberg
Pages203-206
ISBN (Electronic)9783642364990
ISBN (Print)9783642364983
DOIs
Publication statusPublished - 2013
Externally publishedYes

Publication series

NameInterstitial Prostate Brachytherapy

Cite this

Pieters, B. R., & Geijsen, E. D. (2013). Results of PDR treatments: The AMC PDR experience. In Interstitial Prostate Brachytherapy (pp. 203-206). (Interstitial Prostate Brachytherapy). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-36499-0_17
Pieters, B. R. ; Geijsen, E. D. / Results of PDR treatments: The AMC PDR experience. Interstitial Prostate Brachytherapy. Springer Berlin Heidelberg, 2013. pp. 203-206 (Interstitial Prostate Brachytherapy).
@inbook{0929cbac35fe499491c68388e2586241,
title = "Results of PDR treatments: The AMC PDR experience",
abstract = "Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 {\%}. The incidence of grade 2–3 rectal complications is limited (12–15 {\%}). The incidence of grade 2–3 urinary toxicity is 15–26.9 {\%}. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.",
author = "Pieters, {B. R.} and Geijsen, {E. D.}",
year = "2013",
doi = "10.1007/978-3-642-36499-0_17",
language = "English",
isbn = "9783642364983",
series = "Interstitial Prostate Brachytherapy",
publisher = "Springer Berlin Heidelberg",
pages = "203--206",
booktitle = "Interstitial Prostate Brachytherapy",

}

Pieters, BR & Geijsen, ED 2013, Results of PDR treatments: The AMC PDR experience. in Interstitial Prostate Brachytherapy. Interstitial Prostate Brachytherapy, Springer Berlin Heidelberg, pp. 203-206. https://doi.org/10.1007/978-3-642-36499-0_17

Results of PDR treatments: The AMC PDR experience. / Pieters, B. R.; Geijsen, E. D.

Interstitial Prostate Brachytherapy. Springer Berlin Heidelberg, 2013. p. 203-206 (Interstitial Prostate Brachytherapy).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - Results of PDR treatments: The AMC PDR experience

AU - Pieters, B. R.

AU - Geijsen, E. D.

PY - 2013

Y1 - 2013

N2 - Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 %. The incidence of grade 2–3 rectal complications is limited (12–15 %). The incidence of grade 2–3 urinary toxicity is 15–26.9 %. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.

AB - Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 %. The incidence of grade 2–3 rectal complications is limited (12–15 %). The incidence of grade 2–3 urinary toxicity is 15–26.9 %. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84954609442&origin=inward

U2 - 10.1007/978-3-642-36499-0_17

DO - 10.1007/978-3-642-36499-0_17

M3 - Chapter

SN - 9783642364983

T3 - Interstitial Prostate Brachytherapy

SP - 203

EP - 206

BT - Interstitial Prostate Brachytherapy

PB - Springer Berlin Heidelberg

ER -

Pieters BR, Geijsen ED. Results of PDR treatments: The AMC PDR experience. In Interstitial Prostate Brachytherapy. Springer Berlin Heidelberg. 2013. p. 203-206. (Interstitial Prostate Brachytherapy). https://doi.org/10.1007/978-3-642-36499-0_17